{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T21:47:14Z","timestamp":1771710434113,"version":"3.50.1"},"reference-count":5,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaci-global.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology: Global"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jacig.2023.100081","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T22:58:48Z","timestamp":1675810728000},"page":"100081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and tolerability of Evusheld in patients with CVID: The Mayo Clinic experience"],"prefix":"10.1016","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2600-1306","authenticated-orcid":false,"given":"Jacqueline D.","family":"Squire","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell M.","family":"Pitlick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine M.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avni Y.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacig.2023.100081_bib1","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jaip.2021.11.030","article-title":"Low IgG trough and lymphocyte subset counts are associated with hospitalization for COVID-19 in patients with primary antibody deficiency","volume":"10","author":"Kuster","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2023.100081_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2022.109097","article-title":"COVID-19-related health outcomes in people with primary immunodeficiency: a systematic review","volume":"243","author":"Drzymalla","year":"2022","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jacig.2023.100081_bib3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jaci.2020.09.010","article-title":"Coronavirus disease 2019 in patients with inborn errors of immunity: an international study","volume":"147","author":"Meyts","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2023.100081_bib4","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jama.2021.24931","article-title":"Tixagevimab and cilgavimab (Evusheld) for pre-exposure prophylaxis of COVID-19","volume":"327","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jacig.2023.100081_bib6","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.jaci.2022.03.026","article-title":"The arrival of SARS-CoV-2-neutralizing antibodies in a currently available commercial immunoglobulin","volume":"149","author":"Miller","year":"2022","journal-title":"J Allergy Clin Immunol"}],"container-title":["Journal of Allergy and Clinical Immunology: Global"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829323000061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829323000061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T13:10:40Z","timestamp":1757423440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772829323000061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2772829323000061"],"URL":"https:\/\/doi.org\/10.1016\/j.jacig.2023.100081","relation":{},"ISSN":["2772-8293"],"issn-type":[{"value":"2772-8293","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and tolerability of Evusheld in patients with CVID: The Mayo Clinic experience","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology: Global","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacig.2023.100081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}],"article-number":"100081"}}